Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1977 1
1978 1
1979 1
1981 2
1988 1
2002 1
2004 2
2005 3
2006 3
2007 7
2008 14
2009 10
2010 17
2011 25
2012 20
2013 13
2014 24
2015 21
2016 19
2017 19
2018 11
2019 11
2020 27
2021 29
2022 4
Text availability
Article attribute
Article type
Publication date

Search Results

253 results
Results by year
Filters applied: . Clear all
Page 1
Long-Acting Cabotegravir and Rilpivirine after Oral Induction for HIV-1 Infection.
Orkin C, Arasteh K, Górgolas Hernández-Mora M, Pokrovsky V, Overton ET, Girard PM, Oka S, Walmsley S, Bettacchi C, Brinson C, Philibert P, Lombaard J, St Clair M, Crauwels H, Ford SL, Patel P, Chounta V, D'Amico R, Vanveggel S, Dorey D, Cutrell A, Griffith S, Margolis DA, Williams PE, Parys W, Smith KY, Spreen WR. Orkin C, et al. Among authors: overton et. N Engl J Med. 2020 Mar 19;382(12):1124-1135. doi: 10.1056/NEJMoa1909512. Epub 2020 Mar 4. N Engl J Med. 2020. PMID: 32130806 Clinical Trial.
Long-Acting Injectable Cabotegravir + Rilpivirine for HIV Maintenance Therapy: Week 48 Pooled Analysis of Phase 3 ATLAS and FLAIR Trials.
Rizzardini G, Overton ET, Orkin C, Swindells S, Arasteh K, Górgolas Hernández-Mora M, Pokrovsky V, Girard PM, Oka S, Andrade-Villanueva JF, Richmond GJ, Baumgarten A, Masiá M, Latiff G, Griffith S, Harrington CM, Hudson KJ, St Clair M, Talarico CL, Patel P, Cutrell A, Van Eygen V, D'Amico R, Mrus JM, Wu S, Ford SL, Chow K, Roberts J, Wills A, Walters N, Vanveggel S, Van Solingen-Ristea R, Crauwels H, Smith KY, Spreen WR, Margolis DA. Rizzardini G, et al. Among authors: overton et. J Acquir Immune Defic Syndr. 2020 Dec 1;85(4):498-506. doi: 10.1097/QAI.0000000000002466. J Acquir Immune Defic Syndr. 2020. PMID: 33136751 Free PMC article. Clinical Trial.
Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 48-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study.
Overton ET, Richmond G, Rizzardini G, Jaeger H, Orrell C, Nagimova F, Bredeek F, García Deltoro M, Swindells S, Andrade-Villanueva JF, Wong A, Khuong-Josses MA, Van Solingen-Ristea R, van Eygen V, Crauwels H, Ford S, Talarico C, Benn P, Wang Y, Hudson KJ, Chounta V, Cutrell A, Patel P, Shaefer M, Margolis DA, Smith KY, Vanveggel S, Spreen W. Overton ET, et al. Lancet. 2021 Dec 19;396(10267):1994-2005. doi: 10.1016/S0140-6736(20)32666-0. Epub 2020 Dec 9. Lancet. 2021. PMID: 33308425 Clinical Trial.
Reply.
Elopre L, Kudroff K, Westfall AO, Overton ET, Mugavero MJ. Elopre L, et al. Among authors: overton et. J Acquir Immune Defic Syndr. 2018 Feb 1;77(2):e22. doi: 10.1097/QAI.0000000000001517. J Acquir Immune Defic Syndr. 2018. PMID: 29319658 Free PMC article. No abstract available.
Gas chromatography.
Eiceman GA, Gardea-Torresdey J, Overton E, Carney K, Dorman F. Eiceman GA, et al. Among authors: overton e. Anal Chem. 2004 Jun 15;76(12):3387-94. doi: 10.1021/ac0400663. Anal Chem. 2004. PMID: 15193115 Review. No abstract available.
Gas chromatography.
Eiceman GA, Gardea-Torresdey J, Overton E, Carney K, Dorman F. Eiceman GA, et al. Among authors: overton e. Anal Chem. 2002 Jun 15;74(12):2771-80. doi: 10.1021/ac020210p. Anal Chem. 2002. PMID: 12090664 Review. No abstract available.
Sometimes, more is better.
Overton ET. Overton ET. J Infect Dis. 2012 Mar 1;205(5):697-9. doi: 10.1093/infdis/jir838. Epub 2012 Jan 24. J Infect Dis. 2012. PMID: 22275400 Free PMC article. No abstract available.
Metabolic consequences of HIV: pathogenic insights.
Willig AL, Overton ET. Willig AL, et al. Among authors: overton et. Curr HIV/AIDS Rep. 2014 Mar;11(1):35-44. doi: 10.1007/s11904-013-0191-7. Curr HIV/AIDS Rep. 2014. PMID: 24390642 Review.
253 results